Pluristem Therapeutics, Inc.
(NASDAQ : PSTI)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
MRNAModerna, Inc. -0.08%132.190.0%$1230.60m
OCGNOcugen, Inc. -2.56%8.740.0%$941.39m
NVAXNovavax, Inc. 10.59%174.8492.9%$613.91m
REGNRegeneron Pharmaceuticals, Inc. 2.71%461.572.7%$556.12m
AMGNAmgen, Inc. 2.62%227.731.3%$540.12m
GILDGilead Sciences, Inc. 2.20%64.621.0%$516.91m
ILMNIllumina, Inc. -0.19%398.853.5%$484.87m
VRTXVertex Pharmaceuticals, Inc. 2.02%211.981.9%$458.30m
ALXNAlexion Pharmaceuticals, Inc. 1.11%150.102.0%$339.49m
BIIBBiogen, Inc. 2.71%270.711.7%$305.38m
CRSPCRISPR Therapeutics AG -0.73%114.650.6%$304.78m
BNGOBioNano Genomics, Inc. 3.62%7.150.0%$275.81m
EXASEXACT Sciences Corp. 0.51%121.6418.4%$251.13m
SGENSeagen Inc. 2.68%149.355.8%$225.25m
PACBPacific Biosciences of California, Inc. 1.70%29.277.2%$176.23m

Company Profile

Pluristem Therapeutics, Inc. is a clinical stage company, which engages in cell therapy development. It develops placenta-based cell therapy product candidates for the treatment of multiple ischemic, inflammatory and hematologic conditions. The firm focuses on the development, clinical trials and manufacturing of cell therapeutics and related technologies. Its products include Clinical Pipeline, PLX-Immune, PLX-PAD, and PLX-R18. The company was founded by Doron Shorrer on May 11, 2001 and is headquartered in Haifa, Israel.